Structure, function and regulation of versican: The most abundant type of proteoglycan in the extracellular matrix

Acta Medica Iranica

Volumn 51, Issue 11, 2013, Pages 740-750

  Sotoodehnejadnematalahi, Fattah ^a   Burke, Bernard ^b  

^a ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Extracellular matrix; Proteoglycans; Versican

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; BETA1 INTEGRIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYALURONIC ACID; LOW DENSITY LIPOPROTEIN; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN P53; SECONDARY LYMPHOID TISSUE CHEMOKINE; SELECTIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSFORMING GROWTH FACTOR BETA1; VERSICAN;

ANGIOGENESIS; ATHEROSCLEROSIS; BINDING KINETICS; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; GEL MOBILITY SHIFT ASSAY; HUMAN; INFLAMMATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UPREGULATION; WOUND HEALING;

BASE SEQUENCE; CARBOHYDRATE CONFORMATION; DNA; EXTRACELLULAR MATRIX; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; VERSICANS;

EID: 84900316143     PISSN: 00446025     EISSN: 17359694     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Badylak SF. The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol 2002;13(5):377-83.
2. Daley WP, Peters SB, Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 2008;121(Pt3):255-64.
3. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997;91(4):439-42.
4. Berrier AL, Yamada KM. Cell-matrix adhesion. J Cell Physiol 2007;213(3):565-73.
5. Campbell NE, Kellenberger L, Greenaway J, Moorehead RA, Linnerth-Petrik NM, Petrik J. Extracellular matrix proteins and tumor angiogenesis. J Oncol 2010; 586905.
6. Adams JC, Watt FM. Regulation of development and differentiation by the extracellular matrix. Development 1993;117(4):1183-98.
7. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998;10(5):640-6.
8. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 1999;11(5):634-40.
9. Van Horssen J, Dijkstra CD, de Vries HE. The extracellular matrix in multiple sclerosis pathology. J Neurochem 2007;103(4):1293-301.
10. Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992;6(3):861-70.
11. Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 1996;10(5):598-614.
12. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52.
13. Kresse H, Schonherr E. Proteoglycans of the extracellular matrix and growth control. J Cell Physiol 2001;189(3):266-74.
14. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989;8(10):2975-81.
15. Carulli D, Laabs T, Geller HM, Fawcett JW. Chondroitin sulfate proteoglycans in neural development and regeneration. Curr Opin Neurobiol 2005;15(2):116-20.
16. Naso MF, Zimmermann DR, Iozzo RV. Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 1994;269(52):32999-3008.
17. Iozzo RV, Naso MF, Cannizzaro LA, Wasmuth JJ, McPherson JD. Mapping of the versican proteoglycan gene (CSPG2) to the long arm of human chromosome 5 (5q12-5q14). Genomics 1992;14(4):845-51.
18. Dours-Zimmermann MT, Zimmermann DR. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J Biol Chem 1994;269(52):32992-8.
19. Zako M, Shinomura T, Ujita M, Ito K, Kimata K. Expression of PG-M(V3), an alternatively spliced form of PG-M without a chondroitin sulfate attachment in region in mouse and human tissues. J Biol Chem 1995;270(8):3914-8.
20. Yang BL, Cao L, Kiani C, Lee V, Zhang Y, Adams ME, Yang BB. Tandem repeats are involved in G1 domain inhibition of versican expression and secretion and the G3 domain enhances glycosaminoglycan modification and product secretion via the complementbinding protein-like motif. J Biol Chem 2000;275(28): 21255-61.
21. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005;15(7):483-94.
22. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Wight TN. Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19(7):1630-9
23. Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Morgelin M, Mucignat MT, Colombatti A, Perris R. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 2002;277(49):47626-35.
24. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, Yang BB. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005;16(3):1330-40.
25. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A. Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002;160(2):549-57.
26. Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P. The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007;96(10):1560-8.
27. Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN, Bassols A. V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer 2005;114(6):879-86.
28. Hernandez, D., Miquel-Serra, L., Docampo, M.J., Marco-Ramell, A., Cabrera, J., Fabra, A., and Bassols, A. V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling. J Biol Chem 2010; 286(2): 1475-1485.
29. Rahmani M, Read JT, Carthy JM, McDonald PC, Wong BW, Esfandiarei M, Si X, Luo Z, Luo H, Rennie PS, McManus BM. Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem 2005;280(13):13019-28.
30. Domenzain C, Hernandez D, Miquel-Serra L, Docampo MJ, Badenas C, Fabra A, Bassols A. Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells. J Biol Chem 2009;284(18):12306-17.
31. Lemire JM, Merrilees MJ, Braun KR, Wight TN. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 2002;190(1):38-45.
32. Hinek A, Braun KR, Liu K, Wang Y, Wight TN. Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 2004;164(1):119-31.
33. Perides G, Rahemtulla F, Lane WS, Asher RA, Bignami A. Isolation of a large aggregating proteoglycan from human brain. J Biol Chem 1992;267(33):23883-7.
34. Zimmermann DR, Dours-Zimmermann MT, Schubert M, Bruckner-Tuderman L. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994(5);124:817-25.
35. Landolt RM, Vaughan L, Winterhalter KH, Zimmermann, DR. Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development 1995;121(8):2303-12.
36. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E, Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010;126(3):640-50.
37. Voutilainen K, Anttila M, Sillanpaa S, Tammi R, Tammi M, Saarikoski S, Kosma VM. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003;107(3):359-64.
38. Theocharis AD. Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 2002; 1588(2): 165-172.
39. Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, Tilley WD, Horsfall DJ. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 2003;63(16):4786-91.
40. Schwartz NB, Domowicz M. Proteoglycans in brain development. Glycoconj J 2004;21(6):329-41.
41. Kodama J, Hasengaowa Kusumoto T, Seki N, Matsuo T, Nakamura K, Hongo A, Hiramatsu Y. Versican expression in human cervical cancer. Eur J Cancer 2007;43(9):1460-6.
42. Domenzain C, Docampo MJ, Serra M, Miquel L, Bassols A. Differential expression of versican isoforms is a component of the human melanoma cell differentiation process. Biochim Biophys Acta 2003;1642(1-2): 107-14.
43. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004;18(6):754-6.
44. Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley PJ, Stone JR. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005;4(9):1350-7.
45. Kenagy RD, Plaas AH, Wight TN. Versican degradation and vascular disease. Trends Cardiovasc Med 2006; 16(6): 209-215.
46. Olin KL, Potter-Perigo S, Barrett PH, Wight TN, Chait A. Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells. J Biol Chem 1999;274(49):34629-36.
47. Wight TN, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004;94(9):1158-67.
48. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28(1-2): 233-245.
49. Yamagata M, Suzuki S, Akiyama SK, Yamada KM, Kimata K. Regulation of cell-substrate adhesion by proteoglycans immobilized on extracellular substrates. J Biol Chem 1989;264(14):8012-8.
50. Yamagata M, Saga S, Kato M, Bernfield M, Kimata K. Selective distributions of proteoglycans and their ligands in pericellular matrix of cultured fibroblasts. Implications for their roles in cell-substratum adhesion. J Cell Sci 1993;106(Pt 1):55-65.
51. Sugiura, N, Sakurai K, Hori Y, Karasawa K, Suzuki S, Kimata K. Preparation of lipid-derivatized glycosaminoglycans to probe a regulatory function of the carbohydrate moieties of proteoglycans in cell-matrix interaction. J Biol Chem 1993;268(21):15779-87.
52. Yamagata M, Kimata K. Repression of a malignant cellsubstratum adhesion phenotype by inhibiting the production of the anti-adhesive proteoglycan, PGM/ versican. J Cell Sci 1994; 107(Pt 9): 2581-2590.
53. Wu Y, Chen L, Zheng PS, Yang BB. beta 1-Integrinmediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 2002;277(14):12294-301.
54. Wu Y, Chen L, Cao L, Sheng W, Yang BB. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 2004;117(Pt 11):2227-37.
55. Kawashima H, Atarashi K, Hirose M, Hirose J, Yamada S, Sugahara K, Miyasaka M. Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/ IdoAalpha1-3GalNAc (4,6-O-disulfate) interact with Land P-selectin and chemokines. J Biol Chem 2002;277(15):12921-30.
56. Hirose J, Kawashima H, Yoshie O, Tashiro K, Miyasaka M. Versican interacts with chemokines and modulates cellular responses. J Biol Chem 2001;276(7):5228-34.
57. Wight TN, Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004;94(9):1158-67.
58. Johnson PR. Role of human airway smooth muscle in altered extracellular matrix production in asthma. Clin Exp Pharmacol Physiol 2001;28(3):233-6.
59. Merrilees MJ, Hankin EJ, Black JL, Beaumont B. Matrix proteoglycans and remodelling of interstitial lung tissue in lymphangioleiomyomatosis. J Pathol 2004;203(2):653-60.
60. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, Briner J, Heitz PU, Zimmermann DR. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996;44(4):303-12.
61. Hernandez D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Cabrera J, Fabra A, Bassols A. V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling. J Biol Chem 2010;286(2):1475-85.
62. Zheng PS, Reis M, Sparling C, Lee DY, La Pierre DP, Wong CK, Deng Z, Kahai S, Wen J, Yang BB. Versican G3 domain promotes blood coagulation through suppressing the activity of tissue factor pathway inhibitor-1. J Biol Chem 2006;281(12):8175-82.
63. Schonherr E, Kinsella MG, Wight TN. Genistein selectively inhibits platelet-derived growth factorstimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 1997;339(2):353-61.
64. Cardoso LE, Little PJ, Ballinger ML, Chan CK, Braun KR, Potter-Perigo S, Bornfeldt KE, Kinsella MG, Wight TN. Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways. J Biol Chem 2010;285(10):6987-95.
65. Schonherr E, Jarvelainen HT, Sandell LJ, Wight TN. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versicanlike chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991; 266(26): 17640-17647.
66. Evanko, S.P., Angello, J.C., and Wight, T.N. Formation of hyaluronan-and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19(4):1004-13.
67. Evanko SP, Johnson PY, Braun KR, Underhill CB, Dudhia J, Wight TN. Platelet-derived growth factor stimulates the formation of versican-hyaluronan aggregates and pericellular matrix expansion in arterial smooth muscle cells. Arch Biochem Biophys 2001;394(1):29-38.
68. Zhang Y, Cao L, Yang BL, Yang BB. The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 1998; 273(33):21342-51.
69. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, Kiani C, Adams ME, Ang LC, Paiwand F, Yang BB. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001; 276(17): 14178-86.
70. Zhang Y, Cao L, Kiani C, Yang BL, Hu W, Yang BB. Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like motifs. J Cell Biochem 1999;73(4):445-57.
71. Perissinotto D, Iacopetti P, Bellina I, Doliana R, Colombatti A, Pettway Z, Bronner-Fraser M, Shinomura T, Kimata K, Morgelin M, Lofberg J, Perris R. Avian neural crest cell migration is diversely regulated by the two major hyaluronan-binding proteoglycans PG-M/ versican and aggrecan. Development 2000;127(13):2823-42.
72. Perris R, Perissinotto D, Pettway Z, Bronner-Fraser M, Morgelin M, Kimata K. Inhibitory effects of PG-H/aggrecan and PG-M/versican on avian neural crest cell migration. FASEB J 1996;10(2):293-301.
73. Dutt S, Kleber M, Matasci, M, Sommer L, Zimmermann DR. Versican V0 and V1 guide migratory neural crest cells. J Biol Chem 2006;281(17):12123-31.
74. Fidler PS, Schuette K, Asher RA, Dobbertin A, Thornton SR, Calle-Patino Y, Muir E, Levine JM, Geller HM, Rogers JH, Faissner A, Fawcett JW. Comparing astrocytic cell lines that are inhibitory or permissive for axon growth: the major axon-inhibitory proteoglycan is NG2. J Neurosci 1999;19(20):8778-88.
75. Jones LL, Sajed D, Tuszynski MH. Axonal regeneration through regions of chondroitin sulfate proteoglycan deposition after spinal cord injury: a balance of permissiveness and inhibition. J Neurosci 2003; 23(28): 9276-9288.
76. Tang, X., Davies, J.E., and Davies, S.J. Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. J Neurosci Res 2003;71(13):427-44.
77. Asher RA, Morgenstern DA, Shearer MC, Adcock KH, Pesheva P, Fawcett JW. Versican is upregulated in CNS injury and is a product of oligodendrocyte lineage cells. J Neurosci 2002;22(6):2225-36.
78. Yamada KM, Even-Ram S. Integrin regulation of growth factor receptors. Nat Cell Biol 2002;4(4):E75-6.
79. Adelsman MA, McCarthy JB, Shimizu Y. Stimulation of beta1-integrin function by epidermal growth factor and heregulin-beta has distinct requirements for erbB2 but a similar dependence on phosphoinositide 3-OH kinase. Mol Biol Cell 1999; 10(9): 2861-78.
80. Cabodi S, Moro L, Bergatto E, Boeri Erba E, Di Stefano P, Turco E, Tarone G, Defilippi P. Integrin regulation of epidermal growth factor (EGF) receptor and of EGFdependent responses. Biochem Soc Trans 2004;32(Pt 3):438-42.
81. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000; 12(5): 581-6.
82. Henderson DJ, Copp AJ. Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart. Circ Res 1998;83(5):523-32.
83. Kern CB, Twal WO, Mjaatvedt CH, Fairey SE, Toole BP, Iruela-Arispe ML, Argraves WS. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev Dyn 2006;235(8):2238-47.
84. Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem 1986;261(29):13526-35.
85. Wijelath ES, Murray J, Rahman S, Patel Y, Ishida A, Strand K, Aziz S, Cardona C, Hammond WP, Savidge GF, Rafii S, Sobel M. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 2002;91(1):25-31.
86. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem 1992;267(14):10003-10.
87. Hasegawa K, Yoneda M, Kuwabara H, Miyaishi O, Itano N, Ohno A, Zako M, Isogai Z. Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding ability in solar elastosis. J Invest Dermatol 2007;127(7):1657-63.
88. Mukaratirwa S, van Ederen AM, Gruys E, Nederbragt H. Versican and hyaluronan expression in canine colonic adenomas and carcinomas: relation to malignancy and depth of tumour invasion. J Comp Pathol 2004;131(4):259-70.
89. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004;10(7):2491-8.
90. Syrokou A, Tzanakakis GN, Hjerpe A, Karamanos NK. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 1999;81(7):733-44.
91. Lemire JM, Merrilees MJ, Braun KR, Wight TN. Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 2002;190(1):38-45.
92. Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell 2001;105(7):821-4.
93. Deguchi JO, Yamazaki H, Aikawa E, Aikawa M. Chronic hypoxia activates the Akt and beta-catenin pathways in human macrophages. Arterioscler Thromb Vasc Biol 2009; 29(10): 1664-70.
94. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001;61(16):6050-4.
95. Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, de la Chapelle A, Pellegata NS. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci USA 2002;99(24):15632-7.
96. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88(20): 1442-55.
97. Bossi G, Sacchi A. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007;29(3):272-84.